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Precision Medicine Requires Precision Laboratories
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Molecular pathologists have been champions in advancing Next Generation Sequencing 
(NGS) assays for use in clinical applications such as diagnosis and targeting therapy. The 
report by Lih et al in this issue of The Journal of Molecular Diagnostics presents the latest 
chapter in this story [1]. Unlike the earlier low and medium throughput technologies, the 
massively parallel sequencing by NGS offers the opportunity for simultaneous targeting of 
different genetic alterations that include single nucleotide variants (SNVs), insertions/
deletions (indels), copy number variations (CNVs), and gene fusions. However, validating 
NGS assays remains challenging when it involves processing tissues from a variety of cancer 
types, different sequencing chemistries and instruments and complex methods for data 
analysis applicable to different types of genetic variants in multiple barcoded samples [2]. 
Guidelines and recommendations for NGS assay validation have been developed by a 
variety of organizations including the College of American Pathologists [3], the American 
College of Medical Genetics and Genomics [4] and the Centers for Disease Control and 
Prevention [5]. These general guidelines are useful to laboratories as they seek to provide the 
quality metrics required to validate NGS assays, but details of the study design to assure that 
the NGS assays are fit-for-purpose are still works in progress.
Molecularly Targeted Cancer Therapeutics
Precision medicine is the use of individualized genetic information to select drugs that are 
most effective and least toxic. The ability of precision medicine to improve cancer therapy 
requires the availability of drugs that are active against known genetic changes. Over the 
years, clinical trials have been painstakingly designed to prove that drugs are therapeutically 
effective for tumors with specific mutations. Regulatory approval of these drugs are often 
linked to analytically validated assays for the targeted gene or genes. To date most of these 
companion diagnostic assays have focused on relatively few analyte targets. However, the 
total number of mutations that have evidence for activity as a driver of tumor progression 
and that can be specifically targeted by a specific drug has grown to several thousand, 
shifting the precision medicine paradigm from 1-gene-1 drug to a multigene-many drugs 
model [6]. Multiplex testing strategies are needed to be developed to increase the number of 
tests that can be performed on limited biopsy samples. Furthermore, these methods need to 
be streamlined to provide and validated results in clinically relevant turn-around times.
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Precision Medicine Enables “Genotype to Phenotype” Oncology Trials
The National Cancer Institute (NCI) refers to trials that match molecular features of a tumor 
to a candidate drug as “genotype to phenotype”, i.e. a particular genetic profile predicts 
response to a drug. These trials all require accurate and rapid detection of specific driver 
mutations so that the appropriate therapy can be selected and administered in a timely 
fashion. All require representative tissue biopsies, use complex and sophisticated NGS 
assays, and pipeline bioinformatics to generate reports as well as precision laboratories that 
have validated the assays.
In these clinical trials the NGS assays are used to assign treatment and therefore are 
considered integral assays and require some level of review and regulatory approval. The 
specifics of the study design to validate these assays and the findings about the parameters 
evaluated are novel and merit publication in the scientific literature to provide guidance to 
others. The approach to analytic validation of the targeted NGS assay used in the NCI-
MPACT trial was recently reported in this journal [7]. It is clear that findings from validation 
of the NCI-MPACT assay were helpful to Lih et al in their approach to the NCI-Molecular 
Analysis for Therapy Choice (MATCH) Trial which presented an even broader challenge for 
the laboratories [1].
Unique Challenges of the NCI-MATCH Trial
The NCI-MATCH trial is the largest trial to date to attempt to match tumors to therapeutic 
agents based solely on the identification of presumed driver mutations amenable to specific 
drugs, the actionable mutations of interest (aMOIs) [8]. This phase 2 study shares features 
with other trials that NCI has designated as “genotype to phenotype”, such as ALCHEMIST 
(testing inoperable non-squamous, non-small cell lung cancers), Lung-MAP (testing 
advanced squamous cell lung cancer), and NCI-MPACT (testing solid tumors). Whereas one 
central laboratory could be used in the other trials, NCI-MATCH required four clinical 
molecular diagnostics laboratories (Frederick National Laboratory for Cancer Research, 
Massachusetts General Hospital, the University of Texas MD Anderson Cancer Center, and 
the Yale School of Medicine) accredited through the Clinical Laboratory Improvement 
Amendment. This is because it is being conducted at many clinical sites across the United 
States that participate in NCI’s Clinical Trials Network (as many as 2,400 different clinics). 
The broad geographic distribution of sites contributing tissue for analysis limited the 
feasibility of having testing done at only one central laboratory.
The NCI-MATCH trial targets the largest number of aMOIs to date. The therapy match is 
based on the identification of 4066 MOIs, a subset of which are aMOIs targeted by 24 
different drugs. The full range of genetic alterations are included in these aMOIs - SNVs, 
indels, CNVs, and gene fusions. To capture the full range of these changes, a targeted DNA 
and cDNA based NGS panel is required, thus requiring both DNA and RNA extracts. While 
the sheer number of aMOIs and drugs suggests that precision medicine is poised to have a 
large impact on most cancer patients, the reality is that most aMOIs are rare, and the study’s 
coordinators estimate that nearly two-thirds of tumors screened will not have an aMOI 
identified and will not be able to be matched to a therapy. For the laboratory this presents 
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challenges of validating rare aMOIs as well as increasing the capacity for testing the large 
number of tumors required to identify those with a matched drug.
Finally, the NCI-MATCH trial targets the largest variety of tumors to date. The trial is open 
to adults with solid tumors, lymphomas and myelomas that no longer respond to standard 
therapy. Drugs are matched independent of the origin and histology of the tumor, thus 
allowing the promise of targeted therapy to be extended to rarer tumor types and tumors that 
have a high degree of genetic variability between patients. This means that assay validation 
needs to account for the wide variety of tissue types to be extracted.
Overview of NGS Assay Validation
It is encouraging that NGS-based assays for clinical cancer genomic profiling have 
increasingly been the focus of validation studies [7; 9–11]. Although it is clear that assay 
validation is essential for clinical implementation, it could be questioned what each 
contributes to the literature. To place the study of Lih et al [1] in the appropriate context, 
some of the more recent validation studies with closest similarity to that of Lih et al will be 
reviewed.
A validation study reported by Frampton et al. relied on reference samples of pooled cell 
lines to determine the accuracy of mutant allele frequency, indel length and gene 
amplification in 287 cancer related genes using a capture-based NGS assay. They reported 
95–99% sensitivity ( >99% for SNVs, 98% for indels and 95% for CNAs) and high 
specificity (positive predictive value >99%) [9]. Test accuracy on clinical material was 
evaluated using 249 formalin-fixed paraffin-embedded (FFPE) cancer samples that had base 
substitutions, indels or CNAs identified by alternative clinical diagnostic technologies. 
Agreement was good (96% concordant for base substitutions and indels and 95–100% 
concordant for CNAs) as was reproducibility. Interestingly they noted that 25% of 
concordant samples had an MAF ≤ 10%, emphasizing the need for high sensitivity. 
Applying this assay to 2,221 solid tumors of diverse origin submitted for clinical evaluation, 
95% were successfully tested and 76% of those tumors had a genetic alteration that was 
associated with a targeted treatment option (either clinically available or currently in clinical 
trial).
In a 2013 Journal of Molecular Diagnostics publication, Singh et al. 2013 reported clinical 
validation of an Ion Torrent Ampliseq cancer panel interrogating 740 mutational hotspots in 
46 cancer related genes using the Ion Torrent Personal Genome Machine (PGM)[10]. They 
applied the assay to FFPE from 70 solid tumor samples with known mutations identified 
with orthogonal methods. The NGS assay identified all but one of 66 expected nucleotide 
variants, but was not successful at detection of indels. Based on serial dilution of cell line 
DNA with known allele frequency the assay could reliably detect variants at 10% frequency 
with high intra- and inter-run reproducibility.
There have been two reports of NGS validation for use in other precision oncology clinical 
trials. The Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer 
Targets (MSK-IMPACT) assay uses a custom hybridization capture panel for the targeted 
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sequencing of all exons and selected introns of 341 genes using the Illumina sequencing 
platform [11]. Validation was based on analysis of DNA from 284 FFPE tumor samples with 
known mutations and serial dilutions to establish threshold for detection. The NCI-MPACT 
trial uses an NGS assay to evaluate 380 aMOIs in 20 genes in three targeted pathways. 
These genes were added to the commercially available 46-gene Ion AmpliSeq Cancer 
Hotspot Panel version I, resulting in final primer design encompassing 62 unique genes and 
383 amplicons [7]. The validation included 191 DNA samples including 120 cell lines, 4 
spike-in of plasmid controls including MOI, 17 xenographs and 50 clinical specimens. 
While the study will use FFPE, 118 of the validation samples were fresh frozen. Analytic 
validation included assessment of sensitivity, specificity, accuracy and reproducibility on 
targets sample subsets. Ten proficiency samples were prepared from clinical samples 
previously analyzed by a conventional mutation-detection assay in another CLIA laboratory. 
To establish the NCI-MPACT assay as “fit-for-purpose”, 10 DNA samples were prepared 
according to the NCI-MPACT protocol and assayed four times with the NCI-MPACT assay 
(two independent operators each performing assay twice). The identified aMOIs were 
verified by Sanger sequencing. Both MSK-IMPACT and NCI-MPACT validation studies 
reported high sensitivity and reproducibility for detection of different variants.
Unique Features of NCI-MATCH Validation Study
The validation plan for the NCI-MATCH assay reported by Lih et al [1] included the need to 
assure inter-laboratory comparability between the four laboratories. Several factors probably 
contributed to the success of these networked laboratories. First was the use of a commercial 
assay that was optimized for the MATCH trial. The details of the design and the initial 
validation of what is now known as the Oncomine™ Cancer Panel (OCP, Thermo Fisher 
Scientific) NGS assay has been described [12]. Briefly, there are several key features of this 
assay. The assay was designed to accommodate limitations imposed by FFPE tissues with 
limited quantity and quality of DNA and RNA. Sequencing results from the Ion Torrent 
Personal Genome Machine™ (PGM, Thermo Fisher Scientific) are linked to an informatics 
pipeline using the Torrent Suite (4.4.2) and Ion Reporter (4.4.2) to identify the relevant 
mutations. The initial validation study used 300 FFPE tumor samples and established 
accuracy >95% for selected mutations and gene fusions[12].
The four Clinical Laboratory Improvement Amendment laboratories each conducted 
preliminary testing with the OCP assay system and then held face-to-face meetings to 
develop locked SOPs using the validated PGM instruments for all steps of the OCP using to 
assure uniformity. This included preanalytic considerations of tumor quality and processing, 
as well as extraction, library preparation, sequencing and data analysis. Samples included in 
the validation were selected to represent 256 MOIs targeted by the OCP and previously 
verified by analytically validated assays. A total of 186 clinical samples and 12 cell lines, all 
FFPE, were assayed in a total of 455 sequencing runs. In addition to selecting samples based 
on MOIs, consideration was given to the range of tumor types and tissue likely to be 
submitted in the NCI-MATCH trial. The clinical samples included tumors originating from 
different tissues, including pancreas, melanoma, skin and bone that may present particular 
challenges for sequencing; 18 different tissues sources for DNA and 5 for RNA sequencing. 
Acceptable assay performance characteristics were pre-defined prior to beginning of 
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validation which included (1) an acceptable assay sensitivity pre-specified ≥95% for SNVs, 
and ≥90% each for other variant types within each clinical laboratory and all four 
laboratories combined, (2) acceptable assay specificity pre-specified as ≥99.9% for SNVs, 
≥99.0% for indels and large indels, ≥97.0 for CNVs, and ≥99.0% for gene fusions within 
each laboratory, and (3) acceptable intra-and inter-operator overall concordance pre-defined 
≥99% for each laboratory as well as for combined laboratory results.
The validation study indicated the OCP assay as performed by the four collaborating 
laboratories in NCI-MATCH trial met the expected performance characteristics for its 
intended use in the precision medicine trial. The study used the MATCHBox data 
management system to upload, analyze and report results, verifying the fully functional 
analysis pipeline. Results indicated high reliability (96.98% sensitivity for 265 known 
mutations, and 99.99% specificity), and high reproducibility (99.99% mean inter-operator 
pairwise concordance across four laboratories). The study further demonstrated that the 
assay can be used with multiple tumor tissue types with remarkable level of lower level of 
detection (LOD) for each variant types (2.8% for SNVs, 10.5% for indels, 6.8% for large 
indels, and four copies for CNVs).
Fit-for-purpose assessment of the full assay was based on prospective testing of twenty two 
tumors system, from biopsy collection through reporting. These tumors included 16 different 
tumor types. Evaluation criteria required that the NGS data passed quality control metrics, 
results were successfully uploaded into MATCHBox, and variant calls and treatment 
assignment were correctly reported. In a total of 32 runs (some samples were analyzed by 
multiple laboratories), 29 runs (90.6%) passed quality control metrics. In the 6 samples 
assayed by multiple laboratories, 11 MOIs (8 SNVs, 1 indel, and 2 CNVs) were detected at 
similar allele frequency or copy number in all laboratories (100% concordance).
Conclusion
The validation study reported by Lih et al [1] is another step moving the field closer to the 
time when precision medicine will generate the expected benefits in improved clinical 
outcomes. The NCI-MATCH is the most ambitious “genotype to phenotype” study to date, 
requiring laboratories to achieve the precision required to have a fully transferrable NGS 
assay and pipeline applicable to a broad range of tumors and tissues. As remarkable as this 
achievement is, it is clear that the field is still young. Even with the large number of MOIs 
evaluated and aMOIs matched to drugs, the majority of patients screened will be ineligible 
for the trial. Achieving the full clinical impact of genetically matched therapies has 
complicated uncertainties in interpreting which genetic changes are driver mutations and by 
development of drug resistance. A major limitation of single agent-targeted treatment is the 
inevitable development of resistance, which can be assessed on NGS platforms at the time of 
initial presentation and on subsequent analyses but is not addressed in current NGS trials or 
this commentary. While the success of the NCI-MATCH trial cannot be assured, linking 
precision laboratories to precision medicine trials assures that data used for drug assignment 
will be reliable. Furthermore, the use of a commercial platform and integrated analysis and 
reporting pipeline will greatly facilitate broader translation of any successes. However 
translation to clinical use will require each laboratory to validate the assay in their hands. 
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Published validation studies, such as the one by Lih et al, will serve to point out critical 
components of that process [1].
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